1. Enhancing cell culture performance
I am an energetic and creative innovator with experiences in Biotechnology and Entrepreneurship, with major skills and
competences ranging from a wide array of biological, biochemical and biomolecular techniques to solid principles of
entrepreneurship of high-tech start-ups. Graduation in Pharmaceutical Biotechnology and PhD in Cell Biology, I gained
international experience at the Hospital for Sick Children, Toronto, Canada and in Silicon Valley, California, USA, where I
got the Certificate in Technology Entrepreneurship at Santa Clara University through the Fulbright program. I experienced
the start-up life at Lipinutragen Srl, a spin-off company of the National Research Council of Bologna, and at SiteOne
Therapeutics Inc., a Stanford-based pharmaceutical company. Since September 2010 I am Co-Founder and full-time CEO
of ReMembrane Srl.
ReMembrane is a start-up company in the biotechnology field founded in September 2010, headquartered in Bologna,
Italy. ReMembrane offers innovative products for biological laboratories that enable the development of more reliable
experimental models, in order to foster scientific research and to obtain substantial savings of money for public research
laboratories, pharmaceutical companies, Contract Research and Manufacturing Organizations (CROs and CMOs) and bio-
pharmaceutical manufacturers. Thanks to its lipidomic-based approach, ReMembrane enhances the value of the cell
culture technology, by cell membrane network standardisation and by the development of experimental models that
better reflect in-vivo tissues.
The cell culture industry had a worldwide sales volume of $ 2.38 B in 2010, with trends making the estimates of the sector
very positive in the incoming years, from the use of stem cells to tissue engineering boom and to bio-similar production.
Despite its worldwide spread in all biological laboratories, the cell culture technology is still subject to many problems of
standardisation and variability, which negatively affect budget and timing of university laboratories, pharmaceutical
companies, CRO, CMO and bio-pharmaceutical manufacturers.
ReMembrane proposes the use of its lipid mixes (called ReFEEDs) for the standardization of the membranes of cultured
cells, in order to create experimental models more reliable and closer to their corresponding in-vivo tissues. The
membrane of cultured cells will be kept constant during the culture life, ensuring more reliable scientific experiments and
increasing the performance of the technology for scientific research, for testing drug candidates and for bio-
pharmaceutical manufacturing. Cell culture users can therefore achieve significant scientific and financial benefits,
through a quality increase of experimental data, savings in the number of experiments or trials to be performed,
increased production of recombinant drugs.
ReMembrane combines an analysis service called RePORT, in order to integrate its product pipeline with a monitoring of
the lipid composition of cell culture membranes. Such analysis will also include a statistical data treatment and a lipidomic
comment of results, based on a benchmarking proprietary database. It will also ensure the possibility of obtaining
important experimental data about what is happening at the level of a fundamental cellular compartment, opening new
research perspectives and fields.
ALEXANDROS CHATGILIALOGLU, PhD
ReMembrane SrL
c/o incubatore INNOVAMI, Via Provinciale Selice 47, 40026 Imola (BO)
C.F. / P.IVA 03063141208- Capitale Sociale: 10.200€ i.v.
Tel: 0542366020 - Fax: 0542643970 - www.remembrane.com - info@remembrane.com